Keros Therapeutics, Inc.
KROS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.82 | -0.30 | -0.18 | 1.66 |
| FCF Yield | -27.47% | -10.84% | -5.88% | -4.63% |
| EV / EBITDA | -0.28 | -5.61 | -9.10 | -20.17 |
| Quality | ||||
| ROIC | -35.71% | -49.02% | -39.49% | -23.08% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.86 | 0.81 | 0.67 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -80.41% | – | 26.20% |
| Free Cash Flow Growth | -28.22% | -78.07% | -12.87% | -69.87% |
| Safety | ||||
| Net Debt / EBITDA | 2.91 | 2.08 | 2.56 | 4.06 |
| Interest Coverage | 0.00 | 0.00 | -114,790.00 | -14,093.25 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 458.15 | 2,637.19 | 0.00 | 330.44 |